New treatment strategy including biological agents in patients with systemic lupus erythematosus

Polskie Archiwum Medycyny Wewnetrznej

Volumn 123, Issue 9, 2013, Pages 482-490

  Leszczyński, Piotr ^a,b   Pawlak Buś, Katarzyna ^a,b  

^a Jozef Strus Hospital   (Poland)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Antimalarial drugs; Biological therapy; Immunosuppressive therapy; New treatment strategy; Systemic lupus erythematosus

Indexed keywords

ABATACEPT; ATACICEPT; AZATHIOPRINE; BELIMUMAB; BIOLOGICAL PRODUCT; CD40 LIGAND MONOCLONAL ANTIBODY; CHLOROQUINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; EPRATUZUMAB; GLUCOCORTICOID; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; INTERLEUKIN 10 ANTIBODY; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OCRELIZUMAB; PREDNISONE; RITUXIMAB; RONTALIZUMAB; SIFALIMUMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; ANTIBODY CONJUGATE; ANTIMALARIAL AGENT; IMMUNOLOGIC FACTOR; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ANTIBODY SPECIFICITY; ARTICLE; AVASCULAR NECROSIS; BIOLOGICAL THERAPY; CATARACT; CLINICAL EFFECTIVENESS; CORTICOSTEROID THERAPY; DIABETES MELLITUS; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DRUG COST; DRUG EFFECT; DRUG MEGADOSE; DRUG POTENCY; DRUG PULSE THERAPY; DRUG SAFETY; EYE TOXICITY; FRACTURE; HUMAN; HYPERTENSION; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; ISCHEMIC HEART DISEASE; LONG TERM CARE; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; MAINTENANCE THERAPY; MUSCULOSKELETAL DISEASE; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS; TIME TO TREATMENT; LUPUS ERYTHEMATOSUS, SYSTEMIC;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIMALARIALS; GLUCOCORTICOIDS; HUMANS; IMMUNOCONJUGATES; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 84887236976     PISSN: 00323772     EISSN: 18979483     Source Type: Journal    
DOI: 10.20452/pamw.1891     Document Type: Article

References (50)

1. Berbatsky S, Boivin JF, Joseph L, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum. 2006; 54: 2550-2557.
2. Chambers SA, Allen E, Rahman A, Isenberg D. Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years. Rheumatology (Oxford). 2009; 48: 673-675.
3. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013; 3: 1-150.
4. Merrill JT, Burgos-Vargas R, Westhovens R, et al. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010; 62: 3077-3087.
5. Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012; 64: 1215-1226.
6. Bertsias G, Joannidis JPA, Boletis J, et al.; Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis. 2008; 67: 195-205.
7. Hahn BH, McMahon MA, Wilkinson A, et al.; American College of Rheumatology. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken). 2012; 64: 797-808.
8. Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011; 377: 721-731.
9. Furie R, Petri M, Zamani O, et al.; BLISS-76 Study Group. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011; 63: 3918-3930.
10. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria. The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: measures of overall disease activity. Arthritis Rheum. 2004; 50: 3418-3426.
11. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: systemic review. Ann Rheum Dis. 2010, 69: 20-28.
12. Hernández-Cruz B, Tapia N, Villa-Romero A, et al. Risk factors associated with mortality in systemic lupus erythematosus. A case-control study in a tertiary care center in Mexico City. Clin Exp Rheumatol. 2001; 19: 395-401.
13. Ruiz-Irastorza G, Egurbide M, Pijoan J, et al. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus. 2006; 15: 577-583.
14. Alarcón G, McGwin G, Bertoli A, et al. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis. 2007; 66: 1168-1172.
15. A randomized study of the effect of withdrawing hydroxychloroquine sulphate in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. N Engl J Med. 1991; 324: 150-154.
16. Molad Y, Gorshtein A, Wysenbeek A, et al. Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort. Lupus. 2002; 11: 356-361.
17. Fessler B, Alarcón G, McGwin GJ Jr, et al. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum. 2005; 52: 1473-1480.
18. Meinão IM, Sato EI, Andrade LE, et al. Controlled trial with chloroquine diphosphate in systemic lupus erythematosus. Lupus. 1996; 5: 237-241.
19. Levy R, Vilela V, Cataldo M, et al. Hydroxychloroquine (HCQ) in lupus pregnancy: a double-blind and placebo-controlled study. Lupus. 2001; 10: 401-404.
20. Clowse M, Magder L, Witter F, Petri M. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum. 2006; 54: 3640-3647.
21. Costedoat-Chalumeau N, Amoura Z, Hulot J, et al. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum. 2006; 54: 3284-3290.
22. Cortés-Hernández J, Ordi-Ros J, Paredes F, et al. Clinical predictors of fetal and maternal outcome in systemic lupus erythematosus: a prospective study of 103 pregnancies. Rheumatology (Oxford). 2002; 41: 643-650.
23. Abarientos C, Sperberg K, Schapiro DL, et al. Hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis and its safety in pregnancy. Expert Opin Drug Saf. 2011; 10: 705-714.
24. Marmor MF, Kellner U, Lai TY, et al.; American Academy of Ophthalmology. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophtalmology. 2011; 118: 415-422.
25. Merill JT. Treatment of systemic lupus eythematosus. Bull NYU Hosp Jt Dis. 2012; 70: 172-176.
26. Lennard L, Van Loon JA, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther. 1989; 46: 149-154.
27. Yamamoto K, Okada Y, Nakamura K, et al. Inosine triphosphate pyrophosphatase 94C>A polymorphism: clinical implications for patients with systemic lupus erythematosus treated with azathioprine. Expert Opin Drug Saf. 2010; 9: 447-457.
28. Houssiau FA, Vasconcelos C, D'Cruz D, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 2002; 46: 2121-2131.
29. Petri M. Clinical research in systemic lupus erythematosus: immediate relevance to clinical practice. Int J Rheum Dis. 2011; 14: 1-5.
30. Dooley MA, Jayne D, Ginzler EM, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med. 2011; 365: 1886-1895.
31. Thamer M, Hernán MS, Zhang Y, et al. Prednisone, lupus activity, and permanent organ damage. J Rheumatol. 2009; 36: 560-564.
32. Skaggs BJ, Hahn BH, McMahon M, et al. Accelerated atherosclerosis in patient with SLE-mechanisms and management. Nat Rev Rheumatol. 2012; 14; 8: 214-223.
33. Bourré-Tessier J, Huynh T, Clarke AE, et al. Features associated with cardiac abnormalities in systemic lupus erythematosus. Lupus. 2011; 20: 1518-1525.
34. Ruiz-Irastorza G, Olivares N, Ruiz-Arruzal I, et al. Predictors of major infections in systemic lupus erythematosus. Arthritis Res Ther. 2009; 11: R109.
35. Karim MY, Pisoni CM, Khamashta MA. Update of immunotherapy for systemic lupus erythematosus - what's hot and what's not! Rheumatology (Oxford). 2009; 48: 332-341.
36. Strand V, Leszczyński P, Keiserman M, et al. Immunologic response to long-term epratuzumab treatment in SL0008, an open-label long-term extension study in patients with moderate-to-severe systemic lupus erythematosus. Ann Rheum Dis. 2013; 72 (Suppl 3): 615.
37. Falgarone G, Dhote R, Boissier MC. B-cell targeted treatments for lupus: the journey counts as much as the destination. Joint Bone Spine. 2012; 79: 437-440.
38. Zhang J, Roschke V, Baker KP, et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol. 2001; 166: 6-10.
39. Cheema GS, Roschke V, Hilbert DM, Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum. 2001; 44: 1313-1319.
40. Navarra SV, Guzmán RM, Gallacher AE, et al.; BLISS-52 Study Group. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011; 377: 721-731.
41. van Volenhofen RF, Petri MA, Cervera R, et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis. 2012 71: 1343-1349.
42. Merrill J, Buyon J, Furie R, et al. Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER). Lupus. 2011; 20: 709-716.
43. Ramos-Casals M, Sanz I, Bosch X, et al. B-cell-depleting therapy in systemic lupus erythematosus. Am J Med. 2012; 125: 327-336.
44. Tokunaga M, Saito K, Kawabata D, et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis. 2007; 66: 470-475.
45. Jónsdóttir T, Gunnarsson I, Risselada A, et al. Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response. Ann Rheum Dis. 2008; 67: 330-334.
46. Dórner T, Goldenberg DM. Targeting CD22 as a strategy for treating systemic autoimmune diseases. Ther Clin Risk Manag. 2007; 3: 953-959.
47. Wallace DJ, Kalunian K, Petri MA, et al. Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis. 2013 Jan 12. [Epub ahead of print].
48. Alten R, Maleitzke T. Tocilizumab: A novel humanized anti-interleukin 6 (IL-6) receptor antibody for the treatment of patients with non-RA systemic, inflammatory rheumatic diseases. Ann Med. 2013; 45: 357-363.
49. Aringer M, Graninger WB, Steiner G, Smolen JS. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum. 2004; 50: 3161-3169.
50. Boletis JN, Ioannidis JP, Boki KA, Moutsopoulos HM. Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis. Lancet. 1999; 354: 569-570.